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Editorial on the Research Topic
Novel Strategies for Anti-Tumor Vaccines
The old dream of tumor immunologists is the construction of efficient anti-tumor vaccines to
fight cancer. Anti-tumor vaccine strategies are necessarily focused, however, on patients who are
already affected by the pathology in which the tumor not only has eluded the host initial immune
response but often further creates suppressive mechanisms that keep counteracting the action of
the immune system.
This Research Topic was intended to focus on several aspects of anti-tumor vaccinology and
particularly on ways to increase the potency of anti-tumor vaccines by acting both on facilitating
tumor antigen selection and presentation to cells of adaptive immunity and on reducing the effect
of suppressive mechanisms on these immune responses. We are convinced, however, that to fight
cancer single immune-based approaches cannot stand alone and thus vaccine approaches need to
be complemented by other immune approaches.
Identification of the optimal repertoire of tumor antigens, in particular neoantigens, for the
best use in anti-tumor vaccination is extensively discussed by Garcia-Garijo et al., who provide an
overview of the existing strategies to identify neoantigens and to evaluate their immunogenicity.
Indeed, only a small fraction of all tumor somatic non-synonymous mutations (NSM) identified
represent bona fide immunogenic neoantigens, and even fewer mediate tumor rejection. Thus, the
impact of neoantigens for vaccine purposes may be overestimated (1). A rich source of tumor
antigens that are non-mutated but still highly tumor specific comes from analysis of the HLA
ligandome landscape of tumors. To complement these studies, Fennemann et al. describe how
personalized tumor vaccines containing multiple neoantigens can broaden and enhance the anti-
tumor immune response. They also focus on the issue of the intratumor mutational landscape
containing different tumor cell subclones, temporal and spatial diversity of neoantigen presentation
and burden, and the relation to tumor immunogenicity, all parameters to be taken into account to
improve clinical efficacy of personalized tumor vaccines.
The use of embryonic and pluripotent stem cells for the identification of additional suitable
antigens to induce an optimal anti-tumor response are described by Ouyang et al. Approaches that
combine an autologous induced pluripotent stem cells (iPSC) vaccine with an immune adjuvant
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have demonstrated great promise to elicit potent anti-tumor
responses for cancer treatment. Insights on future directions are
described by the authors.
Targeting tumor-associated antigens with specific antibodies
in association with stimulating cytokines in novel formulations
can be beneficial particularly in case of neoplastic diseases
characterized by the pronounced expression of these antigens as
it is the case of the unique tumor-associated form of MUC1 in
pancreatic ductal carcinoma (PDA) described by Dreau et al..
Interestingly, the treatment results in infiltration of cells that
can mediate ADCC function of phagocytes and reduction of
suppressive regulatory cells, stressing the fact that effective anti-
tumor treatment can also include a drastic modification of the
tumor microenvironment.
Mimicking tumor antigens by approaches of anti-idiotype
responses is revisited by Kohler et al.. They discuss advantages
and limitations of this approach and explain how this old/novel
strategy can be adapted in Biotech-standard production of
therapeutic antibodies. As all nominal antigens, tumor antigens
become immunogenic only if appropriately processed and
presented by antigen presenting cells (APC). A novel therapeutic
strategy of combining personalized vaccines in combination
with standard therapy and anti-PD1 checkpoint inhibitors
is proposed by Bassani-Sternberg et al. as a Phase1b study
in resected pancreatic adenocarcinoma (PDAC) patients. The
vaccine platform is based on autologous dendritic cells (DCs)
loaded with mutated neoantigens and tumor-specific antigens
identified through their original proteo-genomics antigen
discovery pipeline. The addition of nivolumab to boost and
maintain the vaccine effect underscores once more the belief that
multiple immunological approaches should be used for optimal
triggering and maintenance of the anti-tumor immune response.
Ameliorating and/or selecting the optimal DC subpopulation
to present tumor antigens are discussed also by Zeng et al. who
focus on a new type of DC, designated CD137 ligand-induced
DC (CD137L-DCs), that induce strong cytotoxic T cell responses.
They show that superior potency of CD137L-DCs in APC activity
compared to other types of DCs is due to their intrinsic increased
Akt-driven glycolysis, thus suggesting that Akt-driven glycolysis
could be a therapeutic target to manipulate the function of
CD137L-DCs for better clinical efficacy.
Increasing tumor antigen availability and T cell priming
are crucial parameters for the efficient response to anti-cancer
vaccines. Accolla et al. reviewed their work on tumor cells
genetically modified by transfection with the MHC class II
transactivator CIITA. These modified tumor cells can not only
process and present antigens to naïve Th cells but they can also
prime virgin tumor specific T cells. Their experimental approach
has been extended to isolate MHC-II-bound relevant tumor
peptides to formulate novel multipeptide vaccines (MHC-I +
MHC-II- bound) against human hepatocarcinoma, presently in
clinical trial1.
Alternative procedures of tumor antigen presentation and
T cell priming are also discussed by Schluck et al. who
concentrate on artificial APC methods employing biomaterials,
1http://www.hepavac.eu.
highly promising tools to activate T cells and evoke robust in vitro
and in vivo immune responses. In this perspective, they presented
an overview of molecular cues that could be used to selectively
expand T cell subsets that are beneficial for strong anti-tumor
immune responses.
Ways to facilitate triggering of anti-tumor immune
response in vivo have been also analyzed by Loeffler et al.
who studied the immune response of patients undergoing
radio-frequency ablation (RFA) of liver metastasis from
colorectal cancers. RFA induced and/or boosted T cell
responses specific for individual tumor antigens were
frequently detectable, but not sufficient for the rejection of
established tumors, indicating once more that combination
therapies, such as immune checkpoint inhibitors should
be considered.
Oncolytic virus (OV) therapy is also becoming an
interesting strategy not only to treat but also to trigger
and/or increase the anti-tumor immune response for
vaccination purposes as Marchini et al. summarized
in their review. They also provide information about
OV-mediated immune conversion of the tumor
microenvironment. As a case study they focus on the rodent
protoparvovirus H-1PV and its dual role as an oncolytic and
immunomodulatory agent.
Construction of therapeutic vaccines against tumors must
take into account reduced or loss of MHC-I expression in
tumor cells as an important mechanism of immune escape.
Abdelaziz et al. stress this point and present intriguing new
data on unexpected block of MHC-I-restricted tumor antigen
presentation without reduction of cell surface expression of
MHC-I molecule by using a Human Cytomegalovirus (HCMV)-
based vector including a HPV E6/E7 fusion protein in a
murine glioblastoma model. The molecular mechanism of lack
of MHC-I presentation is not fully clear but it seems to
correlate with defects of proteasome function generated by
the HCMV vector. Of course this should be taken in serious
considerations when approaches of tumor peptide vaccination
using HCMV as host for gene sequences of tumor peptides
are used.
In conclusion, we are confident that this Research
Topic will help to better delineate the past and present
problems related to the efficacy of anti-tumor vaccines
and, based on this background, develop new ideas and
strategies to improve their construction and efficacy
for tomorrow.
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